台州市2018/2019年度社区老年人接种流感疫苗的保护效果  

Effectiveness of influenza vaccine among community-dwelling elderly people of Taizhou city during the 2018/2019 influenza season

作　　者：靳妍[1] 符剑[2] 何寒青[2] 邱春华[1] 葛君华[3] 童伟丽 施海云 陈杨[3] 王文宇 王倩倩 王连华[1] 陈怡平[1] 徐一文[1] 刘令初 吕华坤[2] Jin Yan;Fu Jian;He Hanqing;Qiu Chunhua;Ge Junhua;Tong Weili;Shi Haiyun;Chen Yang;Wang Wenyu;Wang Qianqian;Wang Lianhua;Chen Yiping;Xu Yiwen;Liu Lingchu;Lv Huakun(Taizhou Municipal Center for Disease Control and Prevention,Taizhou 318000,Zhejiang,China;Zhejiang Provincial Center for Disease Control and Prevention,Hangzhou 310009,Zhejiang,China;Tiantai County Center for Disease Control and Prevention,Taizhou 317200,Zhejiang,China;Luqiao District Center for Disease Control and Prevention,Taizhou 318050,Zhejiang,China;Yuhuan Municipal Center for Disease Control and Prevention,Taizhou 317600,Zhejiang,China)

机构地区：[1]台州市疾病预防控制中心,浙江台州318000 [2]浙江省疾病预防控制中心,浙江杭州310009 [3]天台县疾病预防控制中心,浙江台州317200 [4]路桥区疾病预防控制中心,浙江台州318050 [5]玉环市疾病预防控制中心,浙江台州317600

出　　处：《中国疫苗和免疫》2021年第1期102-106,共5页Chinese Journal of Vaccines and Immunization

基　　金：2019年台州市科技局第二批市级科技计划项目(1902ky92)。

摘　　要：目的评估台州市2018/2019年度社区老年人接种三价灭活流感疫苗(TIV)的保护效果(VE)。方法运用前瞻性队列研究设计,招募接种和未接种TIV的≥60岁社区老年人随访6个月,观察流感样疾病(ILI)、因ILI就诊、因ILI或肺炎住院、因呼吸或循环系统疾病住院4种临床结局,计算TIV的VE。结果 TIV接种组、未接种组分别纳入研究对象1 048名、1 025名。接种TIV后1-3月预防4种临床结局的VE(95%CI)分别为-25.1(-80.4-13.2)%、-33.1(-99.2-11.1)%、35.8(-124.9-81.7)%和-12.6(-229.2-61.5)%;接种TIV后4-6月分别为25.5(-7.5-48.4)%、35.1(3.0-56.5)%、1.4(-249.1-72.1)%和-11.5(-240.9-63.5)%;接种TIV后1-6月分别为5.9(-24.2-28.7)%、11.6(-18.9-34.3)%、21.7(-99.2-69.2)%和-13.9(-155.5-49.2)%。结论台州市2018/2019年度社区老年人接种TIV对预防ILI病例发病、就诊和相关住院具有一定的保护效果。Objective To evaluate the effectiveness of inactivated trivalent influenza vaccine(TIV) among community-dwelling elderly people during the 2018-2019 influenza season in Taizhou city.Methods We used a prospective cohort study to recruit ≥60-year-old community-dwelling individuals who received TIV or did not receive TIV. We conducted a 6-month follow-up to observe influenza-like illness(ILI), medical visits for ILI, hospitalization for ILI or pneumonia, and hospitalization for respiratory or circulatory diseases. We calculated vaccine effectiveness(VE).Results A total of 1 048 individuals received TIV and 1 025 did not receive TIV in the study. TIV VEs(95%CI) against the four clinical outcomes for a 1-3-month follow-up period were-25.1(-80.4-13.2)%,-33.1(-99.2-11.1)%, 35.8(-124.9-81.7)%, and-12.6(-229.2-61.5)%, respectively;for a 4-6-month follow-up period, VEs were 25.5(-7.5-48.4)%, 35.1(3.0-56.5)%, 1.4(-249.1-72.1)%, and-11.5(-240.9-63.5)%, respectively;and for a 1-6-month follow-up period, VEs were 5.9(-24.2-28.7)%, 11.6(-18.9-34.3)%, 21.7(-99.2-69.2)%, and-13.9(-155.5-49.2)%, respectively.Conclusions TIV vaccination in community-dwelling elderly people showed some, but variable, effectiveness against ILI, ILI-related medical visits and hospitalization during the 2018-2019 season in Taizhou.

关 键 词：流感疫苗 接种 保护效果 流感样疾病 老年人 

分 类 号：R186.3[医药卫生—流行病学]